Clinical Trial Results:
ENSAYO CLINICO FASE II MULTICENTRICO, ABIERTO Y ALEATORIZADO SOBRE EL USO TERAPEUTICO DE LA INFUSION INTRAARTERIAL DE CÉLULAS MONONUCLEADAS DE MÉDULA ÓSEA AUTÓLOGA EN PACIENTES NO DIABÉTICOS CON ISQUEMIA CRÓNICA CRÍTICA DE MIEMBROS INFERIORES
Summary
|
|
EudraCT number |
2009-013636-20 |
Trial protocol |
ES |
Global end of trial date |
29 Dec 2022
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
06 Mar 2024
|
First version publication date |
06 Mar 2024
|
Other versions |
|
Summary report(s) |
Final Report_Summary |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
CMMo/ICC/2009
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Fundación Pública Andaluza Progreso y Salud M.P.
|
||
Sponsor organisation address |
Avda. Américo Vespucio 15 · Edificio S-2 · 2ª Pta, Sevilla, Spain, 41092
|
||
Public contact |
ROSARIO CARMEN MATA ALCÁZAR-CABALLERO, Fundación Pública Andaluza Progreso y Salud M.P., rosario.mata@juntadeandalucia.es
|
||
Scientific contact |
ROSARIO CARMEN MATA ALCÁZAR-CABALLERO, Fundación Pública Andaluza Progreso y Salud M.P., rosario.mata@juntadeandalucia.es
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
29 Dec 2022
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
29 Dec 2022
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
29 Dec 2022
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
Evaluar la seguridad y factibilidad del autotrasplante de células mononucleadas de médula ósea (mo-CMNs) autóloga administradas por vía intraarterial en el miembro afecto de pacientes no diabéticos con isquemia crónica crítica de los miembros inferiores sin posibilidades de revascularización ni otras alternativas terapéuticas.
|
||
Protection of trial subjects |
The trial has been carried out in accordance with the recommendations for Clinical Trials and the evaluation of the product under investigation in humans, which appear in the Declaration of Helsinki,
revised in successive world assemblies (WMA, 2008), and the current Spanish Legislation on Clinical Trials. In addition, the ICH-GPC standards have been followed.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
01 Jul 2009
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Spain: 37
|
||
Worldwide total number of subjects |
37
|
||
EEA total number of subjects |
37
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
37
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||
Recruitment
|
|||||||||||||
Recruitment details |
- | ||||||||||||
Pre-assignment
|
|||||||||||||
Screening details |
- | ||||||||||||
Pre-assignment period milestones
|
|||||||||||||
Number of subjects started |
28 [1] | ||||||||||||
Number of subjects completed |
28 | ||||||||||||
Notes [1] - The number of subjects reported to have started the pre-assignment period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same. Justification: It is detailed in the summary of the clinical report |
|||||||||||||
Period 1
|
|||||||||||||
Period 1 title |
Recruitment and follow-up (overall period)
|
||||||||||||
Is this the baseline period? |
Yes | ||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||
Blinding used |
Not blinded | ||||||||||||
Arms
|
|||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||
Arm title
|
Group 1 | ||||||||||||
Arm description |
- | ||||||||||||
Arm type |
Experimental | ||||||||||||
Investigational medicinal product name |
Unexpanded autologous bone marrow adult mononuclear stem cells
|
||||||||||||
Investigational medicinal product code |
|||||||||||||
Other name |
|||||||||||||
Pharmaceutical forms |
Infusion
|
||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||
Dosage and administration details |
1x10e8 moCMNs
|
||||||||||||
Arm title
|
Group 2 | ||||||||||||
Arm description |
- | ||||||||||||
Arm type |
Experimental | ||||||||||||
Investigational medicinal product name |
Unexpanded autologous bone marrow adult mononuclear stem cells
|
||||||||||||
Investigational medicinal product code |
|||||||||||||
Other name |
|||||||||||||
Pharmaceutical forms |
Injection/infusion
|
||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||
Dosage and administration details |
5x10e8 moCMNs
|
||||||||||||
Arm title
|
Group 3 | ||||||||||||
Arm description |
- | ||||||||||||
Arm type |
Experimental | ||||||||||||
Investigational medicinal product name |
Unexpanded autologous bone marrow adult mononuclear stem cells
|
||||||||||||
Investigational medicinal product code |
|||||||||||||
Other name |
|||||||||||||
Pharmaceutical forms |
Suspension for injection
|
||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||
Dosage and administration details |
1x10e9 moCMNs
|
||||||||||||
|
|||||||||||||
Notes [2] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same. Justification: It is detailed in the summary of the clinical report |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Recruitment and follow-up
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Group 1
|
||
Reporting group description |
- | ||
Reporting group title |
Group 2
|
||
Reporting group description |
- | ||
Reporting group title |
Group 3
|
||
Reporting group description |
- |
|
|||||||||||||
End point title |
Safety and feasibility [1] | ||||||||||||
End point description |
To evaluate the safety and feasibility of autotransplantation of mononucleated marrow cells autologous bone, administered intra-arterially in non-diabetic patients with ischemia chronic critical condition of the lower limbs without the possibility of revascularization or other therapeutic alternatives.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
During the study
|
||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: It is detailed in the summary of the clinical report |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||
Adverse events information [1]
|
|||
Timeframe for reporting adverse events |
From the inclusion of the first patient to the last visit of the last patient
|
||
Assessment type |
Systematic | ||
Dictionary used for adverse event reporting
|
|||
Dictionary name |
MedDRA | ||
Dictionary version |
NA
|
||
Frequency threshold for reporting non-serious adverse events: 1% | |||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: It is detailed in the summary of the clinical report |
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
12 Nov 2009 |
changes in the research team |
||
29 Mar 2011 |
new participating centers are added |
||
08 May 2012 |
The monitoring period is modified |
||
10 Jun 2013 |
The sample size is decreased |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |